Recombinant Mouse IFN-γ: Benchmarks and Immunomodulatory Insights

Executive Summary: Recombinant Mouse IFN-γ (E.coli, His & Strep, Liquid) is a non-covalently linked homodimer with a molecular weight of ~15.6 kDa and >95% purity, confirmed by SDS-PAGE (product details). This cytokine induces class I and II MHC expression, Fc receptors, and adhesion molecules, thereby priming antigen presentation pathways and immune effector functions. Its biological activity—EC50 of 0.3-0.9 ng/mL—has been validated in antiviral L-929 mouse fibroblast assays. Defective MHC-I antigen presentation, as seen in MASH-HCC, can be experimentally restored or assessed using IFN-γ, providing a powerful tool for immunometabolic and tumor immunity studies (Cancer Letters 2026). APExBIO’s formulation is endotoxin-controlled (<1 EU/µg) and supplied as a sterile 1 mg/mL PBS solution, supporting reproducible research workflows.

Biological Rationale

Interferon gamma (IFN-γ) is a type II interferon produced primarily by activated T cells and natural killer (NK) cells. It is pivotal in orchestrating immune surveillance, driving the upregulation of major histocompatibility complex (MHC) molecules on antigen-presenting cells, and potentiating macrophage effector functions. In the context of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma (MASH-HCC), IFN-γ’s capacity to restore or assess antigen presentation is critical, as bile acid retention impairs NLRC5-mediated MHC-I expression and immune recognition (Cancer Letters 2026). Recombinant Mouse IFN-γ allows controlled studies of these mechanisms in vitro and in vivo. For a mechanistic exploration, see Recombinant Mouse IFN-γ: Mechanistic Insights and Immunometabolic Applications, which details how IFN-γ modulates macrophage function; this article extends those principles to tumor antigenicity and bile acid-driven immune escape.

Mechanism of Action of Recombinant Mouse IFN-γ (E.coli, His & Strep, Liquid)

Recombinant Mouse IFN-γ, as supplied by APExBIO, acts by binding to the IFN-γ receptor complex on responsive cells, triggering the JAK-STAT signaling pathway. This leads to transcriptional activation of interferon-stimulated genes, promoting:

• Upregulation of class I and II MHC molecules and Fc receptors, enhancing antigen presentation and immune cell targeting (product page).
• Induction of pro-inflammatory cytokines, chemokines, and adhesion molecules, which are essential for immune cell recruitment and activation.
• Regulation of isotype switching and increased immunoglobulin secretion by B cells.
• Promotion of TH1 cell expansion and differentiation, favoring cellular immunity.
• Activation of macrophage microbicidal activity and antigen processing pathways.

This mechanism is particularly relevant for dissecting immune evasion in tumors with defective antigen presentation, as observed in MASH-HCC (Bile Acid Retention Impairs Antigen Presentation in MASH-HCC). This extends previous insights by demonstrating how IFN-γ can be used to probe or restore immune competence in metabolically dysregulated cancer models.

Evidence & Benchmarks

• The IFN-γ EC50 for inhibiting encephalomyocarditis virus in L-929 mouse fibroblast cells is 0.3–0.9 ng/mL in antiviral cytokine assays (APExBIO product info).
• Purity consistently exceeds 95% as validated by SDS-PAGE, supporting high specificity for research applications (product specifications).
• Endotoxin levels are below 1 EU/µg, minimizing risk of LPS-like effects in immunomodulatory cytokine research (APExBIO).
• Bile acid retention in MASH-HCC models impairs NLRC5-mediated MHC-I antigen presentation; IFN-γ serves as a positive control to assess restoration of antigenicity (Cancer Letters 2026).
• Genetic inactivation of NLRC5 abolishes IFN-γ-induced MHC-I expression in bile acid–accumulating tumor cells, confirming the pathway specificity (Cancer Letters 2026).
• For advanced protocol guidance, Recombinant Mouse IFN-γ: Optimizing Antigenicity Assays in MASH-HCC provides assay workflows; this article adds comparative benchmarks relevant to metabolic immune escape.

Applications, Limits & Misconceptions

Recombinant Mouse IFN-γ is widely employed in antiviral cytokine assays, macrophage activation studies, and TH1 cell differentiation assays to dissect immune effector mechanisms. It is specifically valuable for:

• Restoring or measuring antigenicity in metabolically challenged tumor models, such as MASH-HCC (Cancer Letters 2026).
• Dissecting mechanisms of immune escape due to metabolic reprogramming or bile acid accumulation.
• Serving as a standard in immunomodulatory cytokine research to benchmark restoration of MHC expression and function (Recombinant Mouse IFN-γ in Tumor Antigenicity and Immunotherapy), which this article updates by providing new evidence from metabolic disease models.
• Evaluating the synergy of IFN-γ with immune checkpoint blockade or metabolic modulators in advanced preclinical models.

Common Pitfalls or Misconceptions

• IFN-γ does not restore antigenicity in tumor models with complete loss of NLRC5, as this transcription factor is required for MHC-I induction (Cancer Letters 2026).
• High endotoxin content in recombinant proteins can confound results; APExBIO’s stringent endotoxin control (<1 EU/µg) addresses this risk (product page).
• Repeated freeze-thaw cycles may degrade protein activity; aliquoting is recommended for consistent results (APExBIO).
• This reagent is not intended for clinical or diagnostic use—research applications only.
• IFN-γ alone cannot overcome immune escape driven by irreversible genetic lesions unrelated to antigen presentation pathways.

Workflow Integration & Parameters

Integrating Recombinant Mouse IFN-γ into immunomodulatory assays requires attention to concentration, timing, and cell system compatibility. For workflow translation and troubleshooting, see Applied Workflows with Recombinant Mouse IFN-γ in Antigenicity Research; this article adds protocol parameterization and benchmarks relevant to MASH-HCC models.

Protocol Parameters

• Protein concentration: Use 0.2–10 ng/mL for in vitro cytokine stimulation of mouse immune cells; antiviral activity is observed at EC50 0.3–0.9 ng/mL in L-929 fibroblasts.
• Vehicle: Protein supplied in sterile PBS at 1 mg/mL; dilute freshly into culture media.
• Storage: Store at −20 to −70 °C; avoid repeated freeze-thaw cycles by aliquoting upon receipt.
• Endotoxin control: Confirm product is <1 EU/µg to avoid LPS-driven immune activation.
• Positive control: Use IFN-γ as a benchmark for restoration of MHC-I antigen presentation in metabolic dysfunction models.
• Negative control: Include NLRC5 knockout or bile acid–overloaded tumor cells to confirm pathway specificity.

Conclusion & Outlook

Recombinant Mouse IFN-γ (E.coli, His & Strep, Liquid) from APExBIO is a validated immunomodulatory tool, enabling studies that probe antigen presentation, antiviral responses, and macrophage activation with high specificity and reproducibility. Its utility is underscored in models of metabolic immune escape, such as MASH-HCC, where it allows for functional restoration and benchmarking of antigenicity. The integration of IFN-γ into combinatorial immunotherapy protocols—especially in conjunction with metabolic modulators—represents a promising strategy, as seen with FXR agonists restoring immune competence in preclinical models (Cancer Letters 2026). Future directions include refining dose-response relationships in complex tissue environments and further standardizing functional readouts across laboratories.